Medicilon 19th Anniversary

Medicilon welcome the year of 2023 and also welcome the 20th year of success.

19 years of overcoming obstacles, 19 years of non-stop innovation and 19 years of R&D acceleration, Medicilon, as a professional biopharmaceutical preclinical comprehensive R&D service CRO, covers the entire process of preclinical new drug research such as drug discovery, pharmaceutical research and preclinical research, in addition of expanding the CDMO service and the global development.

The 19-year-old Medicilon has accompanied 1,710 clients to success, empowered 268 INDs to be approved and moved forward to the clinical stage, and witnessed the China's biopharmaceutical innovation power from the beginning to the world.  This contains the trust of partners, the power of persistence and faith in overcoming countless difficulties.  It is also the sum of the wisdom, sweat, persistence and happiness of the Medicilon colleagues. (Data as of the end of June 2022)

Medicilon will continue to deepen the field of preclinical research and development of biopharmaceutical through high efficiency, high quality, and cost-effective R&D services.  Medicilon will also give full play to its advantages in technology, platform, and resources to empower the global pharmaceutical industry!